Home >> Cardiovascular >> Cardiovascular >> Baby Food >> Technology & Media >>

Venous (Vein) Thrombosis - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 90 | Code: MRS - 18253

Venous (Vein) Thrombosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Venous (Vein) Thrombosis - Pipeline Review, H1 2015’, provides an overview of the Venous (Vein) Thrombosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous (Vein) Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous (Vein) Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Venous (Vein) Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Venous (Vein) Thrombosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Venous (Vein) Thrombosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Venous (Vein) Thrombosis Overview 8
Therapeutics Development 9
Pipeline Products for Venous (Vein) Thrombosis - Overview 9
Pipeline Products for Venous (Vein) Thrombosis - Comparative Analysis 10
Venous (Vein) Thrombosis - Therapeutics under Development by Companies 11
Venous (Vein) Thrombosis - Therapeutics under Investigation by Universities/Institutes 12
Venous (Vein) Thrombosis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Venous (Vein) Thrombosis - Products under Development by Companies 16
Venous (Vein) Thrombosis - Products under Investigation by Universities/Institutes 17
Venous (Vein) Thrombosis - Companies Involved in Therapeutics Development 18
Astellas Pharma Inc. 18
Bayer AG 19
Bristol-Myers Squibb Company 20
Eisai Co., Ltd. 21
F. Hoffmann-La Roche Ltd. 22
Generex Biotechnology Corporation 23
Merrion Pharmaceuticals Plc 24
Regado Biosciences, Inc. 25
Venous (Vein) Thrombosis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
AB-012 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
apixaban - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AS-1468240 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BAY-1213790 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
BMS-593214 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
E-5539 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
enoxaparin sodium - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ER-410660 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
fondaparinux sodium - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Ichorcumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NPB-06 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
REG-2 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
rivaroxaban - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RNAi Oligonucleotide for DVT - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules for Hematological Disorders and Cancer - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
TRX-1 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Venous (Vein) Thrombosis - Recent Pipeline Updates 58
Venous (Vein) Thrombosis - Dormant Projects 76
Venous (Vein) Thrombosis - Discontinued Products 77
Venous (Vein) Thrombosis - Product Development Milestones 78
Featured News & Press Releases 78
Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents 78
Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits 78
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 80
Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 81
Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 82
Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 83
Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 85
Mar 14, 2014: U.S. FDA Approves Eliquis (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 86
Jan 07, 2014: TeaRx announces initiation of Phase II clinical trial of its TeaRx, an oral Factor Xa inhibitor 87
Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE 87
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List of Tables
Number of Products under Development for Venous (Vein) Thrombosis, H1 2015 9
Number of Products under Development for Venous (Vein) Thrombosis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Venous (Vein) Thrombosis - Pipeline by Astellas Pharma Inc., H1 2015 18
Venous (Vein) Thrombosis - Pipeline by Bayer AG, H1 2015 19
Venous (Vein) Thrombosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 20
Venous (Vein) Thrombosis - Pipeline by Eisai Co., Ltd., H1 2015 21
Venous (Vein) Thrombosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 22
Venous (Vein) Thrombosis - Pipeline by Generex Biotechnology Corporation, H1 2015 23
Venous (Vein) Thrombosis - Pipeline by Merrion Pharmaceuticals Plc, H1 2015 24
Venous (Vein) Thrombosis - Pipeline by Regado Biosciences, Inc., H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Venous (Vein) Thrombosis Therapeutics - Recent Pipeline Updates, H1 2015 58
Venous (Vein) Thrombosis - Dormant Projects, H1 2015 76
Venous (Vein) Thrombosis - Discontinued Products, H1 2015 77

List of Figures
Number of Products under Development for Venous (Vein) Thrombosis, H1 2015 9
Number of Products under Development for Venous (Vein) Thrombosis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Products, H1 2015 15
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Top 10 Targets, H1 2015 27
Number of Products by Stage and Top 10 Targets, H1 2015 28
Number of Products by Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 30
Number of Products by Top 10 Routes of Administration, H1 2015 31
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32
Number of Products by Top 10 Molecule Types, H1 2015 33
Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing